Drugs / cAd3-EBOZ
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02354404 | Jan 2015 → Apr 2017 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02267109 | Oct 2014 → Apr 2016 | Ebola hemorrhagic fever | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 1 | NCT02240875 | Sep 2014 → Aug 2017 | Ebola hemorrhagic fever | University of Oxford | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02289027 | Oct 2014 → Jun 2015 | Ebola hemorrhagic fever | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cAd3-EBO Z | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02240875 ↗ |
| Known as | ChAd3-EBO-Z | “BACKGROUND: The 2014 west African Zaire Ebola virus epidemic prompted worldwide partners to accelerate clinical development of replication-defective chimpanzee adenovirus 3...” PMID 26546548 ↗ Nov 20151“On the basis of a request by WHO, we aimed to assess the safety and immunogenicity of the monovalent, recombinant, chimpanzee adenovirus type-3 vector-based Ebola Zaire vaccine...” PMID 26725450 ↗ Dec 2015 |
| Modality | Vaccine | “The purpose of this study is to assess two new Ebola vaccines: cAd3-EBO Z at 3 different doses, and a second vaccine, MVA-BN® Filo, at 3 different doses.” NCT02240875 ↗ |
| Route | Intramuscular | “Single dose of cAd3-EBO Z at 1 x 10\^10 vp intramuscularly” NCT02240875 ↗ |